(ATRC) AtriCure - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 1.433m USD | Total Return: -15.2% in 12m
Avg Turnover: 24.7M
Qual. Beats: 6
Rev. Trend: 99.9%
Qual. Beats: 0
Warnings
Interest Coverage Ratio 0.4 is critical
Altman Z'' -2.46 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
AtriCure Inc. (ATRC) is a medical technology company specializing in surgical ablation systems, left atrial appendage (LAA) exclusion devices, and cryoneurolysis for pain management. The company’s product portfolio includes the Isolator Synergy clamps, EPi-Sense systems for long-standing persistent atrial fibrillation, and the AtriClip LAA exclusion system. These devices utilize radio frequency (RF) and cryothermic energy to treat cardiac arrhythmias and provide temporary nerve blocks.
The company operates within the high-growth cardiac surgery sub-sector, where demand is largely driven by the increasing global prevalence of atrial fibrillation. AtriCure utilizes a hybrid distribution model, employing a direct sales force in major markets like the United States while utilizing independent distributors for international reach. This capital-intensive business model relies on continuous research and development to maintain regulatory approvals and clinical adoption.
Investors can find deeper technical analysis and valuation metrics for this stock on ValueRay. The company is headquartered in Mason, Ohio, and has maintained a focus on minimally invasive surgical solutions since its incorporation in 2000.
- Expansion of AtriClip sales drives high-margin left atrial appendage exclusion revenue
- Adoption of EPi-Sense systems for long-standing persistent atrial fibrillation increases market share
- CryoSPHERE probe utilization for cardiothoracic pain management accelerates non-arrhythmia growth
- Regulatory approval timelines for new ablation technologies impact long-term valuation
- Hospital capital expenditure cycles influence surgical instrument and hardware procurement levels
| Net Income: -4.59m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 8.44 > 1.0 |
| NWC/Revenue: 43.56% < 20% (prev 39.63%; Δ 3.92% < -1%) |
| CFO/TA 0.10 > 3% & CFO 64.4m > Net Income -4.59m |
| Net Debt (-60.5m) to EBITDA (23.5m): -2.57 < 3 |
| Current Ratio: 4.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.0m) vs 12m ago 3.49% < -2% |
| Gross Margin: 75.47% > 18% (prev 0.75%; Δ 7.47k% > 0.5%) |
| Asset Turnover: 89.37% > 50% (prev 81.14%; Δ 8.23% > 0%) |
| Interest Coverage Ratio: 0.38 > 6 (EBITDA TTM 23.5m / Interest Expense TTM 7.24m) |
| A: 0.37 (Total Current Assets 313.7m - Total Current Liabilities 73.2m) / Total Assets 644.0m |
| B: -0.64 (Retained Earnings -413.1m / Total Assets 644.0m) |
| C: 0.00 (EBIT TTM 2.77m / Avg Total Assets 617.8m) |
| D: -2.71 (Book Value of Equity -412.8m / Total Liabilities 152.3m) |
| Altman-Z'' = -2.46 = D |
| DSRI: 0.98 (Receivables 71.3m/63.3m, Revenue 552.2m/480.1m) |
| GMI: 0.99 (GM 75.47% / 74.60%) |
| AQI: 0.89 (AQ_t 0.44 / AQ_t-1 0.49) |
| SGI: 1.15 (Revenue 552.2m / 480.1m) |
| TATA: -0.11 (NI -4.59m - CFO 64.4m) / TA 644.0m) |
| Beneish M = -3.12 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 28.81 with a total of 930,164 shares traded.
Over the past week, the price has changed by +1.16%,
over one month by -0.79%,
over three months by -8.94% and
over the past year by -15.24%.
AtriCure has received a consensus analysts rating of 4.22. Therefore, it is recommended to buy ATRC.
- StrongBuy: 4
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 47 | 63.1% |
P/E Forward = 357.1429
P/S = 2.5946
P/B = 2.9688
P/EG = 10.0
Revenue TTM = 552.2m USD
EBIT TTM = 2.77m USD
EBITDA TTM = 23.5m USD
Long Term Debt = 61.0m USD (from longTermDebt, last quarter)
Short Term Debt = 3.13m USD (from shortTermDebt, last quarter)
Debt = 85.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 10.8m
Net Debt = -60.5m USD (calculated: Debt 85.7m - CCE 146.2m)
Enterprise Value = 1.37b USD (1.43b + Debt 85.7m - CCE 146.2m)
Interest Coverage Ratio = 0.38 (Ebit TTM 2.77m / Interest Expense TTM 7.24m)
EV/FCF = 25.58x (Enterprise Value 1.37b / FCF TTM 53.6m)
FCF Yield = 3.91% (FCF TTM 53.6m / Enterprise Value 1.37b)
FCF Margin = 9.72% (FCF TTM 53.6m / Revenue TTM 552.2m)
Net Margin = -0.83% (Net Income TTM -4.59m / Revenue TTM 552.2m)
Gross Margin = 75.47% ((Revenue TTM 552.2m - Cost of Revenue TTM 135.5m) / Revenue TTM)
Gross Margin QoQ = 77.39% (prev 74.43%)
Tobins Q-Ratio = 2.13 (Enterprise Value 1.37b / Total Assets 644.0m)
Interest Expense / Debt = 8.45% (Interest Expense 7.24m / Debt 85.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = 2.19m (EBIT 2.77m * (1 - 21.00%))
Current Ratio = 4.29 (Total Current Assets 313.7m / Total Current Liabilities 73.2m)
Debt / Equity = 0.17 (Debt 85.7m / totalStockholderEquity, last quarter 491.7m)
Debt / EBITDA = -2.57 (Net Debt -60.5m / EBITDA 23.5m)
Debt / FCF = -1.13 (Net Debt -60.5m / FCF TTM 53.6m)
Total Stockholder Equity = 481.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.74% (Net Income -4.59m / Total Assets 644.0m)
RoE = -0.51% (Net Income TTM -4.59m / Total Stockholder Equity 894.3m)
RoCE = 0.29% (EBIT 2.77m / Capital Employed (Equity 894.3m + L.T.Debt 61.0m))
RoIC = 0.51% (NOPAT 2.19m / Invested Capital 427.8m)
WACC = 8.39% (E(1.43b)/V(1.52b) * Re(8.49%) + D(85.7m)/V(1.52b) * Rd(8.45%) * (1-Tc(0.21)))
Discount Rate = 8.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 2.45%
[DCF] Terminal Value 75.31% ; FCFF base≈53.6m ; Y1≈53.9m ; Y5≈57.1m
[DCF] Fair Price = 18.61 (EV 881.8m - Net Debt -60.5m = Equity 942.3m / Shares 50.6m; r=8.39% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.59 | # QB: 6
Revenue Correlation: 99.91 | Revenue CAGR: 16.17% | SUE: 0.77 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.02 | Chg30d=N/A | Revisions=+0% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.02 | Chg30d=-68.06% | Revisions=N/A | Analysts=8
EPS current Year (2026-12-31): EPS=0.12 | Chg30d=-12.93% | Revisions=+0% | GrowthEPS=+210.8% | GrowthRev=+13.2%
EPS next Year (2027-12-31): EPS=0.35 | Chg30d=-5.65% | Revisions=-20% | GrowthEPS=+186.2% | GrowthRev=+12.2%
[Analyst] Revisions Ratio: -20%